It's possible another class could be added to create a three drug combo (IDX-719?) but this is pure speculation.
Well, the Phase 2 combo trial of simeprevir + samatasvir recently began in GT1b and GT4. I think that combo, in combo with ribavirin and perhaps without, has a chance to suffice in those GTs. Combo trials adding the JNJ non-nuke are also due to begin 2H this year.
Market Data 
Markets 
AI
